Abstract
The claims at issue in this case are directed to sitagliptin dihydrogenphosphate (``sitagliptin DHP''), a dipeptidyl peptidase-IV (``DP-IV'') inhibito......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
